Loading…
← CockpitCompetitor Analysis › XVIVO.ST Xvivo Perfusion ABOpen in the cockpit ↗

Xvivo Perfusion ABXVIVO.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Medical Specialties
Momentum laggard 4
Mkt cap
$611M
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$1.99M
20-day average traded
Fwd P/E
53.1×
forward earnings
ROIC−WACC
-5.5 pp
WACC 10.0%
Hurdle
+1 pp
Req g minus delivered
Next earnings
71 days
28 Jan 2027
Close · SEKSEK 197.20
1D+0.6%
1W-4.3%
1M-14.1%
3M-29.6%
6M-32.4%
YTD+5.7%
1Y+20.2%
ATR %3.9%
52w lowhigh37.4% off high

What Xvivo Perfusion does

Employees: 210

Xvivo Perfusion at a glance

Size Xvivo Perfusion (XVIVO.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $611M, the 159th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 197.20 on 18 Nov 2026.

Performance Over six months the shares fell 32.4%, against -6.6% for the median peer and +2.8% for the Sweden market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth Revenue grew 17.8% over the last twelve months (peer median +16.1%); the operating margin is 12.1% (peer median 7.5%).

Valuation It trades at 53.1× forward earnings against a peer median of 21.1× (2nd most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.5 points below its cost of capital (10.0% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 94XVIVO.ST 67
Six months, rebased to 100: Xvivo Perfusion against the median of its 20 peers (local-currency closes).

Xvivo Perfusion financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 959MSEK 812MSEK 822MSEK 598MSEK 415M
Revenue growth—-1%+38%+44%—
Gross profitSEK 607MSEK 533MSEK 551MSEK 417MSEK 283M
EBITDASEK 199MSEK 163MSEK 183MSEK 69.4MSEK 34.3M
Net incomeSEK 129MSEK 25.2MSEK 172MSEK 91.8MSEK 18.4M
Free cash flown/aSEK 7.34MSEK 40.6MSEK 3.27MSEK 9.67M
Capital expendituren/aSEK 253MSEK 193MSEK 144MSEK 131M
Total debtSEK 121MSEK 125MSEK 34.0MSEK 31.4MSEK 10.0M

Quarterly statements and history in the cockpit →

Xvivo Perfusion competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%688236NANMEDISGHT4728TCMD688581300314OBIO1789PACBQDELSNT301235603122002876XVIVO.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Xvivo Perfusion is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%50×100×688236NANMEDITCMD6885813003141789300952QDELSNT300326301235002876XVIVO.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xvivo Perfusion is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%688236NANMEDI4728TCMD6885811789SNT300326002876XVIVO.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Xvivo Perfusion is the large dot.

Xvivo Perfusion competitors and peer comparison

How Xvivo Perfusion compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xvivo Perfusion against its 20 peers (data as of 18 Nov 2026)
MeasureXVIVO.STPeer medianRank in peer set
1-month return-14.1%-3.4%4th lowest of 19
6-month return-32.4%-6.6%4th lowest of 19
Distance from 52-week high-37.4%-30.1%7th lowest of 20
Revenue growth (TTM)+17.8%+16.1%9th highest of 20
Operating margin12.1%7.5%8th highest of 20
Forward P/E53.1×21.1×2nd most expensive of 14
Growth the price implies (Req g, 7 yrs)35.9%0.3%most demanding of 11
Growth delivered (Del g)+35.2%+13.1%2nd highest of 11
Hurdle (Req g minus delivered)+0.7 pp-13.2 pp3rd most demanding of 11
ROIC minus cost of capital-5.5 pp+1.2 pp6th lowest of 19
EV / EBITDA30.3×13.2×2nd most expensive of 8
Net debt / EBITDA-1.0×-0.7×4th least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%17.4×-8.5%+2.2%
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
vVARDIS VVVVUnited States$594Mn/a+148%-72%n/an/an/a
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%21.1×8.4%+12.0%
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%18.9×0.4%+27.8%
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%12.0×n/an/a
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%n/an/an/a
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%39.7×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%n/an/an/a
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%33.7×n/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%n/an/an/a
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%

Questions

Which companies are Xvivo Perfusion's closest peers?
The cockpit's peer set: Beijing Chunlizhengda Medical Instruments (688236.SS), Nanosonics (NAN.AX), Medistim (MEDI.OL), Sight Sciences (SGHT), Sahajanand Medical Technologies (SMT.NS), vVARDIS (VVVV), SunMax Biotechnology (4728.TWO), Tactile Systems Technology (TCMD).
Is Xvivo Perfusion expensive compared with its peers?
On forward p/e it trades at 53.1× against a peer median of 21.1×, 2nd most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Xvivo Perfusion stock performed?
Over six months to 18 Nov 2026 the shares returned -32.4% against -6.6% for the median peer; over one year +20.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.